Lung Cancer

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Jonathan W. Riess, MD, MS, discusses advancements, as well as unmet needs in the management of thymic malignancies.

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Misako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.

China’s NMPA has accepted an sBLA for ivonescimab in first-line, PD-L1–positive non–small cell lung cancer.

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

The EMA’s CHMP has recommended the approval of amivantamab plus chemotherapy for pretreated, EGFR-mutated advanced non–small cell lung cancer.

First-line sugemalimab plus chemotherapy has been approved in Europe for metastatic non–small cell lung cancer.

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.